Tag Archives: Geoffrey Porges

What’s wrong with Celgene as shares get clobbered? Nothing, actually.

The News: Celgene Corp. (Summit NJ) plummeted 20% Thursday (October 26, 2017) to $99.99 after releasing third-quarter earnings. And it wasn’t so much third-quarter revenue, which was up 10% year over year,… Read more »

Amgen’s osteoporosis med almost a home run in latest trial; fate now murky on heart safety

The News: Amgen Inc. (Thousand Oaks CA) and UCB SA (Brussels) no longer expect their experimental osteoporosis drug to win US approval this year after a higher rate of serious… Read more »

Gilead’s slog downward accelerates; CEO’s growth reassurances need action–now

The News: Gilead Sciences Inc. (Foster City CA) on Tuesday (February 7, 2017) said that it anticipates full-year revenue for 2017 to be in the range of $22.5 billion to… Read more »

New Biogen pick for CEO inherits tough job; markets aren’t exactly enthralled–yet

Biogen Inc. (Cambridge MA) said Monday (December 19, 2016) it has named veteran biopharmaceutical executive Michel Vounatsos, head of the company’s commercial organization, its next chief executive. Mr. Vounatsos will succeed George Scangos, who announced earlier this… Read more »

Drugmakers’ Pricing Power Helped by Exclusivity Rights: JAMA

The U.S., which spends more on drugs than any other country, might contain costs by limiting market exclusivity for brand-name medicines and changing coverage requirements for government health plans, some… Read more »